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Pragmatic clinicians divide breast tumours into three 
types: those requiring hormonal therapy, those requiring 
anti-human epidermal growth factor receptor 2 (HER2) 
therapy and those requiring chemotherapy. Happily, 
these types correspond to the main groups immortalised 
by Chuck Perou in the ‘intrinsic’ classiﬁ  cation of breast 
cancer (luminal, HER2-enriched and basal-like) [1], but it 
is worth noting that the clustering of gene expression 
proﬁ  les  reﬂ   ects primarily cell type and is only very 
indirectly related to drug responses. Th   e major biological 
distinction is between cells with a precursor phenotype 
(basal-like, also called luminal progenitor) and cells with 
a diﬀ   erentiated phenotype that equips them to build 
ducts or secrete milk [2]. Th  e latter are luminal in the 
sense that they resemble the luminal (inner) cell layer of 
mammary epithelia. In this sense, the HER2-enriched 
pheno  type is clearly luminal. To avoid confusion I 
sometimes use the term ‘broad luminal’ to describe the 
shared features of anatomically luminal cells. Surpris-
ingly, the unique feature that distinguishes the HER2-
enriched group from other luminal tumours is not the 
presence of an ERBB2 amplicon but the absence of 
oestrogen receptor (ER) expression. At ﬁ  rst glance, this 
loss of ER expression looks like a minor detail in the 
expression proﬁ   le but it has profound consequences. 
Without ER the cells maintain their broad luminal proﬁ  le 
but stray into a shadowy world known to pathologists as 
apocrine metaplasia. Fibrocystic disease is a common 
manifestation of apocrine metaplasia in benign mammary 
tissue. Th   e critical point is that androgen replaces oestro-
gen as the driving force behind diﬀ  erentiation. Tumours 
with this phenotype have been given various names, 
including HER2-enriched, ER–/androgen receptor (AR)+, 
and triple negative/AR+. I proposed the term ‘molecular 
apocrine’ because: 1, it is not an unpronounceable 
acronym; 2, many HER2+ tumours have an ‘intrinsic’ 
luminal proﬁ  le rather than a HER2-enriched proﬁ  le; 3, 
many tumours with a HER2-enriched proﬁ  le lack ERBB2 
amplicons; 4, it is not biologically meaningful to cast 
relatively well diﬀ  erentiated tumours as a subdivision of 
triple negative tumours (a term widely understood to 
mean progenitor or basal-like); and 5, apocrine glands 
are androgen-driven glands with a secretory mechanism 
akin to that of mammary glands, so the term captures the 
distinctive biology that deﬁ   nes the group [3]. When 
pathologists say the mammary gland is a sweat gland, 
they mean an apocrine gland not an eccrine gland. From 
an evolutionary perspective, the mammary gland is 
derived from an apocrine gland in the skin of an erstwh  ile 
frog (a synapsid) [4]. Somewhere along the way oestrogen 
supplanted androgen and the mammary gland was born. 
All luminal cells express AR but it is normally held in 
check by ER, whose role is to police the frontier between 
civilised mammary society and apocrine metaplasia. 
Putting together the biology, the histology, the expression 
proﬁ  le, and the genetic data on ERBB2 ampliﬁ  cation and 
germline PTEN (phosphatase and tensin homolog) muta-
tion [1,5], it seems clear that pathological activation of 
the HER2 signalling pathway in the absence of protective 
ER signalling sets the stage for mammary cells to revert 
to their ancestral apocrine fate.
Two recent chromatin immunoprecipitation sequen-
cing (ChIP-seq) papers have shed important new light on 
the mechanism of molecular apocrine tumour formation 
[6,7]. To many scientists the precision with which ChIP-
seq can map transcription factor binding on a genome-
wide scale is nothing short of miraculous. Indeed, 
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Two recent studies on a rare androgen-dependent 
form of breast cancer have shed light on the biology 
of luminal tumours and reinforced the view that 
interfering with androgen signalling may have a place 
in the therapy of some forms of breast cancer.
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in AR and ER binding that might accompany apocrine 
metaplasia. Th   e new papers both used breast cancer cell 
lines to model molecular apocrine tumours [8]. If they 
have a weakness, it is perhaps that the available cell lines 
may not fully capture the spirit of apocrine metaplasia. 
Setting aside this caveat, the results show an impressive 
role for androgens in the biology of these tumours. Both 
studies built on work by the same groups showing that 
FOXA1 (Forkhead box A1) renders nearby DNA more 
accessible to ER and AR. In the new work they used 
ChIP-seq to map AR and FOXA1 binding in MDA-
MB-453 molecular apocrine cells. Th  ey compared it to 
the pattern of ER and FOXA1 binding in MCF7 breast 
cancer cells, and to the pattern of AR and FOXA1 binding 
in LNCaP prostate cancer cells. Steroid receptors are 
inventive in their choice of partners, particularly in 
prostate cells, but the striking result reported by the 
Carroll lab was the unprecedented extent to which AR 
and FOXA1 work together to bring AR to oestrogen 
response elements in MDA-MB-453 cells [7]. Th  is 
explains why molecular apocrine tumours cluster with 
luminal tumours in gene expression studies: AR 
substitutes for ER at the enhancers of ER target genes to 
sustain the broad luminal proﬁ  le. At the same time, AR 
binds to the enhancers of a smattering of its own target 
genes to give the expression proﬁ  le its apocrine ﬂ  avour. 
Th   e Brown lab went a step further by linking activation of 
HER2 signalling to AR, but perhaps not as one might 
have expected. Rather than HER2 signalling to AR, as has 
been reported by others [9], they found that AR signals to 
HER2. It does so by inducing the expression of HER3 
(ERBB3), a dimerisation partner for HER2. Th   is sets up a 
positive feedback loop between AR and HER2, which is 
exactly what we were hoping to see: in metaplasia the cell 
must ﬂ   ip from a positive feedback loop deﬁ  ning  the 
normal state to a new loop deﬁ  ning the metaplastic state. 
Th  e route from AR to HER3 includes an interesting 
detour through WNT signalling: AR activates WNT7B 
expression, which sends β-catenin scuttling into the 
nucleus to help AR transactivate the ERBB3 promoter 
[6].
Th  is work leaves us with a stronger conviction that 
androgens are a worthy therapeutic target in molecular 
apocrine tumours. Th  ere is already one trial under way 
with an anti-androgen drug (bicalutamide) in relapsed 
molecular apocrine tumours (NCT00468715). My own 
preference would be to test abiraterone in these tumours. 
Abiraterone blocks the synthesis of androgens and 
oestrogens, and has shown promise in prostate cancer 
[10]. Since it deprives tumours of both androgens and 
estrogens, classic luminal and molecular apocrine 
tumours should respond equally well to it. Clinicians 
could conﬁ  dently plan and execute such a study without 
waiting endlessly for labs to come up with the perfect 
molecular apocrine biomarker. In fact, they could get the 
diagnosis wrong and the treatment would still work. 
What more could you ask?
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